SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : FDA THRESHOLD: LOWER-RISK BIOTECH INVESTING
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: opalapril who wrote (2)9/28/1999 11:40:00 AM
From: aknahow  Read Replies (2) of 75
 
Opalapril, I like the potential for continuity of posters that may no longer post elsewhere but I just don't understand the concept. Suppose XOMA had somehow received approval for Neuprex for Meningococcemia and then the news hit that P III for trauma was halted for lack of efficacy. The stock would have gone down 50% , with the only difference being it would have declined from a higher level.

I just do not see how one avoids regulatory or even just the risk involved in trials.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News